The stiff-person syndrome: An autoimmune disorder affecting neurotransmission of γ-aminobutyric acid

Annals of Internal Medicine

Volumn 131, Issue 7, 1999, Pages 522-530

  Levy, Lucien M ^a,b   Dalakas, Marinos C ^a   Floeter, Mary Kay ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BACLOFEN; DIAZEPAM; IMMUNOGLOBULIN; VIGABATRIN;

ANTIBODY TITER; AUTOIMMUNITY; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MOTOR CORTEX; MUSCLE RIGIDITY; MUSCLE SPASM; NEUROTRANSMITTER RELEASE; PLASMAPHERESIS; PRIORITY JOURNAL; STIFF MAN SYNDROME; TREATMENT PLANNING;

EID: 0033527354     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-7-199910050-00008     Document Type: Conference Paper

References (63)

1. Moersh FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome): report of a case and some observations in 13 other cases. Mayo Clin Proc. 1956;31:421-7.
2. Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc. 1989;64:629-36.
3. McEvoy K. Stiff-man syndrome. Semin Neurol. 1991;11:197-205.
4. Mitsumoto H, Schwartzman MJ, Estes ML, Chou SM, La Franchise EF, De Camilli P, et al. Sudden death and paroxysmal autonomic dysfunction in stiff-man syndrome. J Neurol. 1991;238:91-6.
5. Toro C, Jacobowitz DM, Hallett M. Stiff-man syndrome. Semin Neurol. 1994;:154-8.
6. Meinck HM, Ricker K, Hulser PJ, Schmid E, Peiffer J, Solimena M. Stiff man syndrome: clinical and laboratory findings in eight patients. J Neurol. 1994;241:157-66.
7. Saiz A, Graus F, Valldeoriola F, Valls-Sole J, Tolosa E. Stiff-leg syndrome: a focal form of stiff-man syndrome. Ann Neurol. 1998;43:400-3.
8. Howard FM Jr. A new and effective drug in the treatment of the stiff-man syndrome: preliminary report. Proc Mayo Clin. 1963;38:203-12.
9. Meinck HM, Ricker K, Conrad B. The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry. 1984; 47:280-7.
10. Floeter MK, Valls-Sole J, Toro C, Jacobowitz D, Hallett M. Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome. Neurology. 1998;51:85-93.
11. Sandbrink F, Syed NA, Dalakas M, Hallett M, Floeter MK. Increased motor cortex excitability in stiffperson syndrome: a paired pulse TMS study. Electroencephalogr Clin Neurophysiol. 1998;107:90P-91P.
12. Jonas P, Bischofberger J, Sandkuhler J. Corelease of two fast neurotransmitters at a central synapse. Science. 1998:281:419-24.
13. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988; 318:1012-20.
14. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med. 1990;322:1555-60.
15. Solimena M, De Camilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci. 1991;14:452-7.
16. Solimena M, Butler MH, De Camilli P. GAD, diabetes, and Stiff-Man syndrome: some progress and more questions. J Endocrinol Invest. 1994;17: 509-20.
17. Vincent A, Grimaldi LM, Martino G, Davenport C, Todd I. Antibodies to 1251-glutamic acid decarboxylase in patients with stiff man syndrome. J Neurol Neurosurg Psychiatry. 1997;62:395-7.
18. Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol. 1996; 156:818-25.
19. Butler MH, Solimena M, Dirkx R Jr, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med. 1993;178:2097-106.
20. Ellis MT, Atkinson MA. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med. 1996;2:148-53.
21. Layzer RB. Stiff-man syndrome - an autoimmune disease? [Editorial] N Engl J Med. 1988;318:1060-2.
22. Barker RA, Marsden CD. Successful treatment of stiff man syndrome with intravenous immunoglobulin [Letter]. J Neurol Neurosurg Psychiatry. 1997;62: 426.
23. Harding AE, Thompson PD, Kocen RS, Batchelor JR, Davey N, Marsden CD. Plasma exchange and immunosuppression in the stiff man syndrome [Letter]. Lancet. 1989;2:915.
24. Hummel M, Durinovic-Bello I, Bonifacio E, Lampasona V, Endl J, Fessele S, et al. Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus. J Neurol Neurosurg Psychiatry. 1998;65:204-8.
25. Karlson EW, Sudarsky L, Ruderman E, Pierson S, Scott M, Helfgott SM. Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum. 1994;37:915-8.
26. Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol. 1998;44:194-201.
27. Pugliese A, Solimena M, Awdeh ZL, Alper CA, Bugawan T, Erlich HA, et al. Association of HLA-DQB1*0201 with stiff-man syndrome. J Clin Endocrinol Metab. 1993;77:1550-3.
28. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med. 1993;328:546-51.
29. De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. 1993;178:2219-23.
30. Yamamoto R, Li X, Winter S, Francke U, Kilimann MW. Primary structure of human amphiphysin, the dominant autoantigen of paraneoplastic stiff-man syndrome, and mapping of its gene (AMPH) to chromosome 7p13-p14. Hum Mol Genet. 1995;4:265-8.
31. Dalakas MC, Li M. Detection and specificity of antibodies against glutamic acid decarboxylase in patients with autoimmune neuromuscular disorders and stiff-person syndrome [Abstract]. Neurology. 1999;52(5 Suppl 1):A122.
32. Lee HK, Yaman A, Nalcioglu O. Homonuclear J-refocused spectral editing technique for quantification of glutamine and glutamate by 1H NMR spectroscopy. Magn Reson Med. 1995;34:253-9.
33. Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology. 1996;47:1567-71.
34. Behar KL, Ogino T. Assignment of resonance in the 1H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Magn Reson Med. 1991;17:285-303.
35. Ryner LN, Sorenson JA, Thomas MA. Localized 2D J-resolved 1H MR spectroscopy: strong coupling effects in vitro and in vivo. Magn Reson Imaging. 1995;13:853-69.
36. Soher BJ, Hurd RE, Sailasuta N, Barker PB. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. Magn Reson Med. 1996;36:335-9.
37. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-9.
38. Bottomley PA. Human in vivo NMR spectroscopy in diagnostic medicine: clinical tool or research probe? Radiology. 1989;170(1 Pt 1):1-15.
39. Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport. 1991;2:131-4.
40. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
41. Cendes F, Stanley JA, Dubeau F, Andermann F, Arnold DL. Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures. Ann Neurol. 1997;41:74-81.
42. Vion-Dury J, Nicoli F, Salvan AM, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy [Letter]. Lancet. 1995;345:60-1.
43. Videen JS, Michaelis T, Pinto P, Ross BD. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. J Clin Invest. 1995;95:788-93.
44. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem. 1992;59:55-61.
45. Holtzman D. Brain creatine kinases and phosphocreatine: an update. Dev Neurosci. 1996;18:522-3.
46. Chu WJ, Hetherington HP, Kuzniecky RI, Simor T, Mason GF, Elgavish GA. Lateralization of human temporal lobe epilepsy by 31P NMR spectroscopic imaging at 4.1 T. Neurology 1998;51:472-9.
47. Tedeschi G, Bertolino A, Righini A, Campbell G, Raman R, Duyn JH, et al. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology. 1995;45:1384-91.
48. Miller BL, Chang L, Booth R, Ernst T, Conford M, Nikas D, et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 1996; 58:1929-35.
49. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg. 1997;87:516-24.
50. Tillakaratne NJ, Medina-Kauwe L, Gibson KM. gamma-Aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Comp Biochem Physiol A Physiol. 1995;112:247-63.
51. Kish SJ, Rajput A, Gilbert J, Rozdilsky B, Chang LJ, Shannak K, et al. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol. 1986;20:26-31.
52. Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F, et al. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. 1996;741:142-52.
53. Cohen L. Stiff-man syndrome. Two patients treated with diazepam. JAMA. 1966;195:222-4.
54. Prevett MC, Brown P, Duncan JS. Improvement of stiff-man syndrome with vigabatrin. Neurology. 1997;48:1133-4.
55. Leach JP, Brodie MJ. Tiagabine. Lancet. 1998;351:203-7.
56. Meinck HM, Tronnier V, Rieke K, Wirtz CR, Flugel D, Schwab S. Intrathecal baclofen treatment for stiff-man syndrome: pump failure may be fatal. Neurology. 1994;44:2209-10.
57. Seitz RJ, Blank B, Kiwit JC, Benecke R. Stiff-person syndrome with antiglutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. J Neurol. 1995;242:618-22.
58. Silbert PL, Matsumoto JY, McManis PG, Stolp-Smith KA, Elliott BA, McEvoy KM. Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology. 1995;45:1893-7.
59. Stayer C, Tronnier V, Dressnandt J. Mauch E, Marquardt G, Rieke K, et al. Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. Neurology. 1997;49:1591-7.
60. Brashear R, Phillips HL 2d. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology. 1991;41:1588-92.
61. Vicari AM, Folli F, Pozza G, Comi GC, Comola M, Canal N, et al. Plasmapheresis in the treatment of stiff-man syndrome [Letter]. N Engl J Med. 1989;320:1499.
62. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997;126:721-30.
63. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.